Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer. [read full story]
|
RELATED
|
|
NEEDHAM, Mass.----Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third...
Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009...
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third...
Celldex Therapeutics, Inc (NASDAQ: CLDX) today reported financial results for the third quarter and nine-month period ended September 30, 2009 Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third...
Cancer by Body Location, Medicines & Remedies, Health Care, Pharmaceuticals, Vaccines, Cancers, Bladder Cancer, Cancer Therapy, Pancreatic Cancer, Patients
